LYC 30937

Drug Profile

LYC 30937

Alternative Names: LYC-30937; LYC-30937-EC; LYC-30937-Enteric coated

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Lycera
  • Class Small molecules
  • Mechanism of Action Adenosine triphosphatase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Ulcerative colitis
  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Plaque psoriasis in USA (PO) (NCT02872285)
  • 01 Sep 2016 Lycera initiates a phase II trial for Ulcerative colitis in USA (NCT02764229)
  • 18 Aug 2016 Lycera plans a phase II trial for Plaque psoriasis in USA (PO) (NCT02872285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top